On Tuesday, Plus Therapeutics Inc (NASDAQ: PSTV) was 3.84% up from the session before settling in for the closing price of $0.68. A 52-week range for PSTV has been $0.16 – $2.31.
Annual sales at Healthcare sector company grew by 46.51% over the past five years. When this article was written, the company’s average yearly earnings per share was at 90.77%. With a float of $98.81 million, this company’s outstanding shares have now reached $99.26 million.
Let’s look at the performance matrix of the company that is accounted for 21 employees.
Plus Therapeutics Inc (PSTV) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Plus Therapeutics Inc stocks. The insider ownership of Plus Therapeutics Inc is 0.46%, while institutional ownership is 3.19%. The most recent insider transaction that took place on Aug 22 ’25, was worth 53,779. In this transaction Director of this company bought 110,000 shares at a rate of $0.49, taking the stock ownership to the 139,327 shares. Before that another transaction happened on May 15 ’25, when Company’s Director proposed sale 36,666 for $0.55, making the entire transaction worth $20,276.
Plus Therapeutics Inc (PSTV) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.37 earnings per share (EPS) during the time that was better than consensus figure (set at -0.56) by 0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.44% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
You can see what Plus Therapeutics Inc (PSTV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.23, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.12 in one year’s time.
